You can find the annual or quarterly income statement of Spruce Biosciences Inc here for insights into the performance and operational efficiency of Spruce Biosciences Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
Total revenue
----
----
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-75.86%697.00K
-80.41%602.00K
-25.64%1.61M
1.93%2.00M
--2.89M
--3.07M
--2.17M
--1.96M
----
----
----
----
----
----
----
----
----
----
Revenue
----
----
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-75.86%697.00K
-80.41%602.00K
-25.64%1.61M
1.93%2.00M
--2.89M
--3.07M
--2.17M
--1.96M
----
----
----
----
----
----
----
----
----
----
Operating expenses
513.37%16.51M
-17.29%11.99M
-55.19%11.10M
-17.79%8.23M
-76.88%2.69M
-0.98%14.49M
76.29%24.77M
-40.17%10.01M
-27.83%11.65M
-3.48%14.63M
16.03%14.05M
44.77%16.73M
35.81%16.14M
29.23%15.16M
32.57%12.11M
1.38%11.56M
1.43%11.88M
19.52%11.73M
9.60%9.13M
19.26%11.40M
--11.71M
--9.82M
--8.34M
--9.56M
R&D expenses
2928.60%12.16M
-30.10%7.58M
-80.87%4.10M
-23.54%5.01M
-105.32%-430.00K
5.04%10.84M
93.31%21.46M
-51.43%6.55M
-38.37%8.09M
-11.91%10.32M
25.58%11.10M
53.50%13.49M
44.88%13.13M
37.66%11.71M
41.24%8.84M
2.14%8.79M
-0.65%9.06M
26.72%8.51M
7.64%6.26M
10.79%8.61M
--9.12M
--6.71M
--5.81M
--7.77M
Depreciation, depletion, and amortization
8914.29%631.00K
4100.00%252.00K
-44.44%5.00K
-70.00%3.00K
-41.67%7.00K
-60.00%6.00K
-43.75%9.00K
-41.18%10.00K
-33.33%12.00K
-21.05%15.00K
-33.33%16.00K
-26.09%17.00K
100.00%18.00K
-9.52%19.00K
20.00%24.00K
27.78%23.00K
-47.06%9.00K
61.54%21.00K
100.00%20.00K
125.00%18.00K
--17.00K
--13.00K
--10.00K
--8.00K
Operating profit
-513.37%-16.51M
17.29%-11.99M
53.89%-11.10M
12.53%-8.23M
73.18%-2.69M
-14.72%-14.49M
-115.64%-24.07M
31.12%-9.41M
28.17%-10.04M
4.29%-12.63M
7.81%-11.16M
-18.18%-13.66M
-17.59%-13.97M
-12.49%-13.20M
-32.57%-12.11M
-1.38%-11.56M
-1.43%-11.88M
-19.52%-11.73M
-9.60%-9.13M
-19.26%-11.40M
---11.71M
---9.82M
---8.34M
---9.56M
Net non-operating interest income (expenses)
Non-operating interest expense
3682.76%1.10M
1772.22%674.00K
-89.29%6.00K
-73.24%19.00K
-65.06%29.00K
-62.89%36.00K
-47.17%56.00K
-40.34%71.00K
-34.65%83.00K
-25.95%97.00K
-17.83%106.00K
8.18%119.00K
35.11%127.00K
50.57%131.00K
46.59%129.00K
25.00%110.00K
17.50%94.00K
-2.25%87.00K
12.82%88.00K
11.39%88.00K
--80.00K
--89.00K
--78.00K
--79.00K
Special income (expenses)
--615.00K
---91.00K
---3.50M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Other non-operating income (expenses)
16.97%765.00K
-0.21%486.00K
-107.01%-40.00K
-95.54%36.00K
-30.28%654.00K
-55.93%487.00K
-56.74%571.00K
-43.22%808.00K
-26.43%938.00K
105.01%1.10M
20.55%1.32M
434.96%1.42M
1125.96%1.27M
829.31%539.00K
2707.69%1.09M
548.78%266.00K
420.00%104.00K
205.26%58.00K
-48.00%39.00K
-19.61%41.00K
--20.00K
--19.00K
--75.00K
--51.00K
Income before tax
-685.15%-16.23M
12.64%-12.27M
37.83%-14.65M
5.29%-8.21M
77.49%-2.07M
-20.78%-14.04M
-136.77%-23.56M
29.81%-8.67M
28.41%-9.18M
9.12%-11.63M
10.71%-9.95M
-8.36%-12.35M
-8.02%-12.82M
-8.75%-12.79M
-21.34%-11.14M
0.40%-11.40M
-0.83%-11.87M
-18.96%-11.76M
-10.15%-9.18M
-19.40%-11.45M
---11.77M
---9.89M
---8.34M
---9.59M
Income tax
----
----
----
----
----
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income after tax
-685.15%-16.23M
12.64%-12.27M
37.83%-14.65M
5.29%-8.21M
77.49%-2.07M
-20.78%-14.04M
-136.77%-23.56M
29.81%-8.67M
28.41%-9.18M
9.12%-11.63M
10.71%-9.95M
-8.36%-12.35M
-8.02%-12.82M
-8.75%-12.79M
-21.34%-11.14M
0.40%-11.40M
-0.83%-11.87M
-18.96%-11.76M
-10.15%-9.18M
-19.40%-11.45M
---11.77M
---9.89M
---8.34M
---9.59M
Net income from continuous operations
-685.15%-16.23M
12.64%-12.27M
37.83%-14.65M
5.29%-8.21M
77.49%-2.07M
-20.78%-14.04M
-136.77%-23.56M
29.81%-8.67M
28.41%-9.18M
9.12%-11.63M
10.71%-9.95M
-8.36%-12.35M
-8.02%-12.82M
-8.75%-12.79M
-21.34%-11.14M
0.40%-11.40M
-0.83%-11.87M
-18.96%-11.76M
-10.15%-9.18M
-19.40%-11.45M
---11.77M
---9.89M
---8.34M
---9.59M
Net income attributable to controlling interests
-685.15%-16.23M
12.64%-12.27M
37.83%-14.65M
5.29%-8.21M
77.49%-2.07M
-20.78%-14.04M
-136.77%-23.56M
29.81%-8.67M
28.41%-9.18M
9.12%-11.63M
10.71%-9.95M
-8.36%-12.35M
-8.02%-12.82M
-8.75%-12.79M
-21.34%-11.14M
0.40%-11.40M
-0.83%-11.87M
-18.96%-11.76M
-10.15%-9.18M
-19.40%-11.45M
---11.77M
---9.89M
---8.34M
---9.59M
Net income attributable to common shareholders
-685.15%-16.23M
12.64%-12.27M
37.83%-14.65M
5.29%-8.21M
77.49%-2.07M
-20.78%-14.04M
-136.77%-23.56M
29.81%-8.67M
28.41%-9.18M
9.12%-11.63M
10.71%-9.95M
-8.36%-12.35M
-8.02%-12.82M
-8.75%-12.79M
-21.34%-11.14M
0.40%-11.40M
-0.83%-11.87M
-18.96%-11.76M
-10.15%-9.18M
-19.40%-11.45M
---11.77M
---9.89M
---8.34M
---9.59M
Basic earnings per share
97.45%-6.68
62.69%-8.94
-1887.74%-11.28
-6846.96%-14.58
-117479.25%-262.25
-8371.47%-23.96
-132.71%-0.57
30.82%-0.21
29.48%-0.22
29.45%-0.28
48.42%-0.24
37.29%-0.30
37.41%-0.32
19.91%-0.40
-20.79%-0.47
1.22%-0.48
-0.13%-0.51
-17.91%-0.50
-4.56%-0.39
-13.76%-0.49
---0.50
---0.42
---0.37
---0.43
Diluted earnings per share
97.45%-6.68
62.69%-8.94
-1887.74%-11.28
-6846.96%-14.58
-117479.25%-262.25
-8371.47%-23.96
-132.71%-0.57
30.82%-0.21
29.48%-0.22
29.45%-0.28
48.42%-0.24
37.29%-0.30
37.41%-0.32
19.91%-0.40
-20.79%-0.47
1.22%-0.48
-0.13%-0.51
-17.91%-0.50
-4.56%-0.39
-13.76%-0.49
---0.50
---0.42
---0.37
---0.43
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
FAQs
How do I read Spruce Biosciences Inc's income statement on TradingKey?
Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.
What is the difference between quarterly and annual income statements?
A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.
What does YOY mean on the income statement page?
YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.
Which income statement metrics matter most when analyzing SPRB stock?
Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.
What was Spruce Biosciences Inc's net income for the year?
Spruce Biosciences Inc posted -38.97M in net income for fiscal year 2025.
How much net income did Spruce Biosciences Inc post in the last quarter?
Spruce Biosciences Inc reported -16.23M in net income for the latest quarter。
What was Spruce Biosciences Inc's annual operating profit?
Spruce Biosciences Inc's operating income was -36.51M for fiscal year 2025.
How is EPS related to the income statement?
EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.